MENTAL DISORDER TREATMENT MARKET ANALYSIS

Mental Disorder Treatment Market, by Disorder Type (Depression, Bipolar Disorder, Schizophrenia, Dementia, Post-traumatic Stress Disorder, and Others), by Medication (Anti-depressants, Anti-anxiety, Mood Stabilizing Medication, and Antipsychotic Medications), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Dec 2020
Code : CMI4326
Pages :175
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of the Middle East
Africa: South Africa, North Africa, and Central Africa

North America is expected to hold dominant position in the global mental disorder treatment market during the forecast period, owing to key companies focusing on inorganic strategies such as strategic collaborations for developing the treatment of various mental disorders such as depression and others. For instance, in June 2020, VistaGen Therapeutics, a pharmaceutical company in the U.S. and EverInsight Therapeutic entered into a strategic collaboration to develop and commercialize ph94b for anxiety disorders in greater China, South Korea, and Southeast Asia.